Lisaftoclax monotherapy demonstrated significant and durable clinical efficacy and a manageable safety profile in patients with heavily pretreated BTK-refractory R/R CLL/SLL, underscoring its utility ...
Please provide your email address to receive an email when new articles are posted on . Higher mutational burden linked with shorter time to first treatment in patients with CLL. Researchers did not ...
Dr. Lipsky presents a second case of a 72-year-old man with symptomatic CLL requiring therapy. Dr. Lipsky presents a second case of a 72-year-old man with symptomatic CLL requiring therapy. High-risk ...
Results from arms C and D of the phase 3 SEQUOIA trial demonstrated that zanubrutinib alone or in combination with venetoclax yields positive results in CLL/SLL subpopulations. In the wake of these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results